Adult: 50-300 mcg daily, usually given in combination w/ cortisone or hydrocortisone. Dosage depends on the severity of the disease and patient’s response.
Oral Salt-losing adrenogenital hyperplasia
Adult: 100-200 mcg daily.
Should be taken with food.
Systemic infections not controlled by antibiotics.
Patient w/ HTN, heart failure, DM, GI diseases (e.g. diverticulitis, active or latent peptic ulcer, ulcerative colitis, fresh intestinal anastomoses, abscess or other pyogenic infection), myasthenia gravis, cataract and/or glaucoma, osteoporosis, thyroid disease, history of seizure disorder. Renal and hepatic impairment. Pregnancy and lactation.
Monitor BP, blood glucose, electrolytes, wt, salt intake.
May increase risk of arrhythmias or toxicity w/ digitalis glycosides. May decrease prothrombin time response to oral anticoagulants. May decrease the therapeutic effect of antidiabetic drugs and aspirin. May diminish response to vaccines. Enhanced hypokalaemic effect w/ amphotericin B or K-depleting diuretics (e.g. benzothiadiazines, furosemide, etacrynic acid). Increased metabolic clearance w/ barbiturates, phenytoin, rifampicin. Increased risk of oedema w/ anabolic steroids particularly C-17 alkylated androgens (e.g. oxymetholone). Estrogens may increase levels of corticosteroid-binding globulin, thereby increasing the bound (inactive) fraction. May antagonise effect of anticholinesterase agents. May enhance neutropenic effect of immunosuppressants. May enhance adverse effect of NSAIDs.
May produce false-negative results in nitrobluetetrazolium test for bacterial infection. May suppress reaction to skin tests.
Description: Fludrocortisone is a corticosteroid w/ glucocorticoid and very potent mineralocorticoid activity. It acts on the renal distal tubules to promote the reabsorption of Na ions and increase the urinary excretion of K and hydrogen ions. Pharmacokinetics: Absorption: Rapidly and completely absorbed from the GI tract. Distribution: Widely distributed throughout the body. Enters breast milk. Plasma protein binding: 70-80%, mainly to globulin fractions. Metabolism: Hepatic. Excretion: Elimination half-life: ≥3.5 hr (plasma); 18-36 hr (biological).
Store between 15-30°C. Protect from excessive heat.
H02AA02 - fludrocortisone ; Belongs to the class of mineralocorticoids. Used in systemic corticosteroid preparations.
Anon. Fludrocortisone. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 08/03/2017 .Buckingham R (ed). Fludrocortisone Acetate. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 08/03/2017 .Fludrocortisone Acetate Tablet (Teva Pharmaceuticals USA, Inc.). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/. Accessed 08/03/2017 .Joint Formulary Committee. Fludrocortisone Acetate. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 08/03/2017 .McEvoy GK, Snow EK, Miller J et al (eds). Fludrocortisone Acetate. AHFS Drug Information (AHFS DI) [online]. American Society of Health-System Pharmacists (ASHP). https://www.medicinescomplete.com. Accessed 08/03/2017 .